Key result
Active malignancy is not associated with higher 30-day mortality in acute pulmonary embolism.
Why the study?
Pulmonary embolism carries significant morbidity and mortality, particularly with malignancy, prompting comparison of laboratory parameters and short- and long-term mortality between malignant and non-malignant cases.
Does the presence of malignancy impact laboratory parameters and survival in patients with acute pulmonary embolism?
Cohort (n=131)
No
Does the presence of malignancy impact laboratory parameters and survival in patients with acute pulmonary embolism?
Absolute Event Rate: 14.6% vs 15.7%
p-value: p=0.869
In patients with acute pulmonary embolism, the presence of malignancy is associated with distinct laboratory profiles and a trend toward worse long-term survival, though short-term mortality remains similar to non-malignant cases.
Malignancy may signal higher long-term PE mortality risk; leaves open whether intensified surveillance or therapies improve outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Günaydın et al. (2026) conducted a cohort in Acute pulmonary embolism (n=131). Malignancy vs. Non-malignant was evaluated on 30-day mortality (p=0.869). In patients with acute pulmonary embolism, the presence of malignancy did not significantly affect 30-day mortality compared to non-malignant patients (14.6% vs. 15.7%, p=0.869).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: